

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 9-12 10-11  
11-12

exact/norm bonds :

5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12



normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom

C:\STNEXP4\QUERIES\09402010a.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 9-12 10-11  
11-12

exact bonds :

5-7 6-9 7-8 7-10 8-9 9-12 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

not  
out

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom

09/402,010

=> d his

(FILE 'HOME' ENTERED AT 18:39:18 ON 07 FEB 2002)

FILE 'REGISTRY' ENTERED AT 18:39:25 ON 07 FEB 2002

L1 SCREEN 1841  
L2 STRUCTURE UPLOADED  
L3 QUE L2 AND L1  
L4 3 S L3  
L5 STRUCTURE UPLOADED  
L6 QUE L5  
L7 10 S L6  
L8 36551 S C5/ESS(S)NC5/ESS(S)C6/ESS  
L9 3 S L3 SUB=L4 SAM  
L10 3 S L3 SUB=L4 FUL

FILE 'CAPLUS' ENTERED AT 18:49:47 ON 07 FEB 2002

L11 1 S WO9935131/PN  
SELECT RN L11 1

FILE 'REGISTRY' ENTERED AT 18:50:03 ON 07 FEB 2002

L12 123 S E1-123  
L13 172 S 1332.25/RID  
L14 60 S L12 AND L13  
L15 63 S L12 NOT L14  
L16 35 S L8 AND L15  
L17 11 S L3 SUB=L8 SAM  
L18 205 S L3 SUB=L8 FUL  
L19 10 S L6 SUB=L8 SAM  
L20 165 S L6 SUB=L8 FUL  
L21 173 S L18 NOT L20


FILE 'CAPLUS' ENTERED AT 18:56:50 ON 07 FEB 2002

L22 8 S L21  
L23 8 S L22 AND PATENT/DT

=> d 13

L3 HAS NO ANSWERS

L1 SCR 1841  
L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE ABB=ON PLU=ON L2 AND L1


=> d 16

L6 HAS NO ANSWERS

09/402,010

L5

STR



Structure attributes must be viewed using STN Express query preparation.

L6

QUE ABB=ON PLU=ON L5

=> d bib abs hitstr 123 1-8

09/402,010

~~DB~~ ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2001:885334 CAPLUS

DN 136:658

TI A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent

IN Coe, Jotham W.; O'Neill, Brian T.; Sands, Steven B.; Dow, Robert L. B.; Harrigan, Edmund P.; Watsky, Eric J.

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1159970	A2	20011205	EP 2001-304806	20010531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

US 2002010192	A1	20020124	US 2001-850042	20010507
---------------	----	----------	----------------	----------

JP 2002012558	A2	20020115	JP 2001-164010	20010531
---------------	----	----------	----------------	----------

PRAI US 2000-208856 P 20000602

AB Pharmaceutical comps. are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical comps. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-obesity agent or wt. loss facilitator or promoter, such as Xenical and Meridia, and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and an anti-obesity agent or wt. loss facilitator are administered substantially simultaneously. A method of treating a disorder or condition in which obesity or an overweight condition predominates, including type 2 diabetes mellitus, hypertension, dislipidemia, and increased mortality in a mammal comprises administering a compn. contg. nicotine receptor partial agonist and an anti-obesity agent.

IT 230615-75-5 249296-44-4 328055-77-2

328055-78-3 328055-79-4 328055-83-0

328055-87-4 328055-88-5 328055-89-6

328055-90-9 328055-92-1 328055-98-7

357424-19-2 357424-20-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(comps. comprising nicotine receptor partial agonist and antiobesity agent for treatment of obesity and related disorders)

RN 230615-75-5 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)

09/402,010




RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-83-0 CAPLUS

CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




09/402,010


RN 328055-87-4 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-  
(9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-  
(9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-  
dimethyl- (9CI) (CA INDEX NAME)




RN 328055-90-9 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-  
phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS  
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-  
methyl- (9CI) (CA INDEX NAME)

09/402,010




RN 328055-98-7 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-  
(9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-  
dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI)  
(CA INDEX NAME)





09/402,010

~~L3~~ ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2001:864711 CAPLUS

~~DN~~ 136:11124

TI Reactive crystallization method to improve particle size

IN Am Ende, David Jon; Crawford, Thomas Charles; Weston, Neil Philip

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 11 pp.


CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1157726	A1	20011128	EP 2001-304422	20010518
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002028475	A2	20020129	JP 2001-153592	20010523
	CN 1326803	A	20011219	CN 2001-119055	20010525
PRAI	US 2000-207629	P	20000526		
AB	This invention provides a method of conducting a simultaneous chem. reaction and controlled crystn. of the product employing impinging fluid jet streams contg. reactants capable of producing the product with desired particle size characteristics. An example is give for reaction and crystn. of ziprasidone to achieve the desired ziprasidone-HCl.H2O.				
IT	<b>249296-44-4</b> RL: PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses) (reactive crystn. method to improve particle size)				
RN	249296-44-4 CAPLUS				
CN	6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)				



IT **375815-87-5P**  
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(reactive crystn. method to improve particle size)

RN 375815-87-5 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 249296-44-4

CMF C13 H13 N3

09/402,010




CM 2

CRN 87-69-4

CMF C4 H6 O6

CDES 1:R2:R\*,R\*

Absolute stereochemistry.



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/402,010

LP3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS

AN 2001:798758 CAPLUS

DN 135:339282

TI Nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent composition for treatment of diseases of cognitive dysfunction in a mammal

IN Coe, Jotham Wadsworth; Sands, Steven Bradley; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Watsky, Eric Jacob

PA USA

SO U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001036949	A1	20011101	US 2001-760966	20010116
	WO 2001085145	A2	20011115	WO 2001-IB681	20010424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-202799 P 20000509

AB A pharmaceutical compn. and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amts. that render the compn. effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS assocd. dementia and schizophrenia. The method of using these compns. is also disclosed.


IT 230615-75-5 249296-44-4 328055-77-2  
328055-78-3 328055-79-4 328055-83-0  
328055-87-4 328055-88-5 328055-89-6  
328055-90-9 328055-92-1 328055-98-7  
357424-19-2 357424-20-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nicotine receptor partial agonist, cholinesterase inhibitor, and estrogenic agent compn. for treatment of diseases of cognitive dysfunction in a mammal)


RN 230615-75-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-  
(9CI) (CA INDEX NAME)


09/402,010




RN 249296-44-4 CAPLUS  
CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)  
(CA INDEX NAME)




RN 328055-77-2 CAPLUS  
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-78-3 CAPLUS  
CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS


09/402,010

CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl- (9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)

09/402,010




RN 328055-92-1 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)




RN 328055-98-7 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 357424-19-2 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



09/402,010

09/402,010

123 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS

AN 2001:762800 CAPLUS

DN 135:322726

TI A pharmaceutical composition containing a nicotine receptor agonist and an analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines

IN Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley; Watsky, Eric Jacob

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001076576	A2	20011018	WO 2001-IB391	20010316
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2001036943	A1	20011101	US 2000-740307	20001218
PRAI	US 2000-195738	P	20000407		
AB	Oral, parenteral or transdermal compns. are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The method of using these compds. and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.				
IT	249296-44-4 328055-77-2 328055-78-3 328055-79-4 328055-83-0 328055-87-4 328055-88-5 328055-89-6 328055-90-9 328055-92-1 357424-19-2 367511-27-1 367511-30-6 367511-38-4				
	RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. contg. nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)				
RN	249296-44-4 CAPLUS				
CN	6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)				




09/402,010




RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS


CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



09/402,010


RN 328055-87-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-  
(9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-  
(9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 328055-92-1 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)

09/402,010




RN 357424-19-2 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 367511-27-1 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 367511-30-6 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-3(5H)-one, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 367511-38-4 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(5H)-one, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)



09/402,010

L23 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS

AN 2001:636053 CAPLUS

DN 135:210949

TI Preparation of aryl-fused azapolycyclic compounds as nicotine binding inhibitors

IN Brooks, Paige Roanne Palmer; Coe, Jotham Wadsworth

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 110 pp.


CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062736	A1	20010830	WO 2001-IB153	20010208
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-514002	A	20000225		
OS	MARPAT 135:210949				
GI					



AB The invention discloses the prepn. of aryl-fused azapolycyclic compds., such as I [R1 = H, alkyl, unconjugated alkenyl, benzyl, X(CO)R13, CH2CH2O-alkyl; R2, R3 = H, alkenyl, alkynyl, hydroxy, nitro, amino, halo, cyano, SOqalkyl, (q = 0 - 2), alkylamino, CO2R4, CONR5R6, SO2NR7R8, COR13, X(CO)R13; R2 and R3, together with the carbons to which they are attached form a 4-7 membered monocyclic ring or a 10-14 membered bicyclic ring; R4-R8, R13 = H, alkyl or R5 and R6, or R7 and R8 together with nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, thiomorpholine; X = alkylene], and their pharmaceutically acceptable salts, as nicotine binding inhibitors (IC50 < 10 .mu.M) in the treatment of neurol. and psychol. disorders. Thus, aryl-fused azapolycyclic compd. I (R1-R3 = H) was prepd. via a multistep synthetic sequence starting from 2-fluorobromobenzene via a cycloaddn. with cyclopentadiene and an amination with triethylbenzylammonium chloride.

IT **357424-19-2P 357424-20-5P**

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of aryl-fused azapolycyclic compds. as nicotine binding

09/402,010

inhibitors)


RN 357424-19-2 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 357424-20-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



IT 230615-07-3P 230615-09-5P 230615-10-8P  
230615-11-9P 230615-12-0P 230615-13-1P  
230615-14-2P 230615-15-3P 230615-16-4P  
230615-17-5P 230615-18-6P 230615-19-7P  
230615-20-0P 230615-21-1P 230615-22-2P  
230615-23-3P 230615-24-4P 230615-25-5P  
230615-26-6P 230615-33-5P 230615-39-1P  
230615-40-4P 230615-44-8P 230615-45-9P  
230615-46-0P 230615-75-5P 249296-44-4P  
287973-24-4P 287973-25-5P 287973-32-4P  
328055-77-2P 328055-78-3P 328055-79-4P  
328055-87-4P 328055-88-5P 328055-89-6P  
328055-90-9P 328055-92-1P 328055-98-7P  
357424-02-3P 357424-03-4P 357424-05-6P  
357424-06-7P 357424-07-8P 357424-08-9P  
357424-09-0P 357424-10-3P 357424-11-4P  
357424-12-5P 357424-13-6P 357424-14-7P  
357424-15-8P 357424-16-9P 357424-17-0P  
357424-18-1P 357424-21-6P 357424-36-3P  
357424-37-4P 357424-39-6P 357424-41-0P  
357424-43-2P 357424-45-4P 357424-47-6P  
357424-49-8P 357424-51-2P 357424-53-4P  
357424-55-6P 357424-57-8P 357424-61-4P  
357424-62-5P 357424-63-6P 357424-64-7P  
357424-65-8P 357424-67-0P 357424-68-1P  
357424-69-2P 357424-70-5P 357424-71-6P  
357424-72-7P 357424-73-8P 357424-74-9P  
357424-75-0P 357424-76-1P 357424-77-2P  
357424-78-3P 357424-79-4P 357424-80-7P  
357424-81-8P 357425-07-1P 357425-09-3P  
357425-10-6P 357425-12-8P 357425-13-9P  
357425-15-1P 357425-17-3P 357425-18-4P  
357425-20-8P 357425-22-0P 357425-24-2P


357425-26-4P 357425-28-6P 357425-29-7P  
 357425-30-0P 357425-31-1P 357425-32-2P  
 357425-34-4P 357425-35-5P 357425-36-6P  
 357425-37-7P 357425-38-8P 357425-39-9P  
 357425-40-2P 357425-41-3P 357425-42-4P  
 357425-43-5P 357425-44-6P 357425-45-7P  
 357425-46-8P 357425-47-9P 357425-48-0P  
 357425-72-0P 357425-73-1P 357425-74-2P  
 357425-75-3P 357425-76-4P 357425-77-5P  
 357425-78-6P 357425-79-7P 357425-80-0P  
 357425-81-1P 357425-82-2P 357425-83-3P  
 357425-84-4P 357425-86-6P 357425-87-7P  
 357425-88-8P 357425-89-9P 357425-90-2P  
 357425-91-3P 357425-92-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)

RN 230615-07-3 CAPLUS


CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-09-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-10-8 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-11-9 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-12-0 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-13-1 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




09/402,010



● HCl

RN 230615-14-2 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-15-3 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-16-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-17-5 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-18-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-19-7 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-20-0 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-  
1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-21-1 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-  
dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-22-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-  
1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-23-3 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-24-4 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-25-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-26-6 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-33-5 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-39-1 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-40-4 CAPLUS


CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-44-8 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-45-9 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-46-0 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 230615-75-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 249296-44-4 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI) (CA INDEX NAME)



RN 287973-24-4 CAPLUS


CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

09/402,010




RN 287973-25-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 287973-32-4 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




09/402,010




RN 328055-79-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-  
(9CI) (CA INDEX NAME)




RN 328055-87-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-  
(9CI) (CA INDEX NAME)



RN 328055-88-5 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-  
(9CI) (CA INDEX NAME)



RN 328055-89-6 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-  
dimethyl- (9CI) (CA INDEX NAME)

09/402,010




RN 328055-90-9 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl- (9CI) (CA INDEX NAME)




RN 328055-92-1 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)



RN 328055-98-7 CAPLUS


CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 357424-02-3 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)


09/402,010




RN 357424-03-4 CAPLUS  
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-  
(9CI) (CA INDEX NAME)




RN 357424-05-6 CAPLUS  
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-,  
1,1-dioxide (9CI) (CA INDEX NAME)



RN 357424-06-7 CAPLUS  
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-  
dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 357424-07-8 CAPLUS  
CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione,  
4,6,7,8,9,10-hexahydro- (9CI) (CA INDEX NAME)



09/402,010


RN 357424-08-9 CAPLUS

CN 6,10-Methano-1H-pyrazino[2,3-h][3]benzazepine-2,3-dione,  
4,6,7,8,9,10-hexahydro-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 357424-09-0 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 357424-10-3 CAPLUS

CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 357424-11-4 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl- (9CI) (CA INDEX NAME)



RN 357424-12-5 CAPLUS


09/402,010

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-13-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl- (9CI) (CA INDEX NAME)




RN 357424-14-7 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 357424-15-8 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 357424-16-9 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl- (9CI) (CA INDEX NAME)

09/402,010




RN 357424-17-0 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-  
1,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 357424-18-1 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-  
1,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 357424-21-6 CAPLUS


CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-  
(9CI) (CA INDEX NAME)




RN 357424-36-3 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)  
(CA INDEX NAME)


09/402,010




RN 357424-37-4 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-  
(9CI) (CA INDEX NAME)




RN 357424-39-6 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-  
(9CI) (CA INDEX NAME)



RN 357424-41-0 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-  
(9CI) (CA INDEX NAME)




RN 357424-43-2 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-  
(9CI) (CA INDEX NAME)



RN 357424-45-4 CAPLUS


09/402,010

CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-  
(9CI) (CA INDEX NAME)




RN 357424-47-6 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-  
(9CI) (CA INDEX NAME)




RN 357424-49-8 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-  
(9CI) (CA INDEX NAME)



RN 357424-51-2 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-  
tetrahydro- (9CI) (CA INDEX NAME)




RN 357424-53-4 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-  
tetrahydro- (9CI) (CA INDEX NAME)




09/402,010



RN 357424-55-6 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-57-8 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-61-4 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-62-5 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).


09/402,010



RN 357424-63-6 CAPLUS

CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, 1,1-dioxide, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-64-7 CAPLUS

CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-dimethyl-, 1,1-dioxide, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-65-8 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-67-0 CAPLUS

CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)

09/402,010


Rotation (+).



RN 357424-68-1 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-69-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-70-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-71-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-, (+)-(9CI) (CA INDEX NAME)

09/402,010


Rotation (+).



RN 357424-72-7 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-,  
(+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-73-8 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-74-9 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-,  
(+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-75-0 CAPLUS

09/402,010

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-76-1 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-77-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-78-3 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357424-79-4 CAPLUS

09/402,010

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-80-7 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357424-81-8 CAPLUS

CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-07-1 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-09-3 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, (+)- (9CI) (CA INDEX NAME)

09/402,010


Rotation (+).



RN 357425-10-6 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-12-8 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-13-9 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-15-1 CAPLUS

CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (+)-(9CI) (CA INDEX NAME)

Rotation (+).


09/402,010



RN 357425-17-3 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-18-4 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 357425-20-8 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 357425-22-0 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




09/402,010



RN 357425-24-2 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-,  
(-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-26-4 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-,  
(-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-28-6 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-  
methyl-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-29-7 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-,  
(-)-(9CI) (CA INDEX NAME)


Rotation (-).

09/402,010




RN 357425-30-0 CAPLUS  
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-,  
1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-31-1 CAPLUS  
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepin-3-amine, 6,7,8,9-tetrahydro-N,N-  
dimethyl-, 1,1-dioxide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 357425-32-2 CAPLUS  
CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-3-  
methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-34-4 CAPLUS  
CN 5,9-Methano-5H-thieno[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-,  
(-)- (9CI) (CA INDEX NAME)

09/402,010


Rotation (-).



RN 357425-35-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-36-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-,  
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-37-7 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-38-8 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-,  
(-)- (9CI) (CA INDEX NAME)

09/402,010


Rotation (-).



RN 357425-39-9 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-,  
(-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-40-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-  
(2-methylpropyl)-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-41-3 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-,  
(-)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-42-4 CAPLUS

09/402,010

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-43-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-44-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-45-7 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-46-8 CAPLUS

09/402,010

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-,  
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-47-9 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-,  
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-48-0 CAPLUS

CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-,  
(-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-72-0 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, (-)-  
(9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-73-1 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-,  
(-)- (9CI) (CA INDEX NAME)

09/402,010


Rotation (-).



RN 357425-74-2 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-75-3 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-76-4 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-77-5 CAPLUS

CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


09/402,010



RN 357425-78-6 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-79-7 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 357425-80-0 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 357425-81-1 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-11-fluoro-7,8,9,10-tetrahydro-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




09/402,010



RN 357425-82-2 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 357425-83-3 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 357425-84-4 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

09/402,010

RN 357425-86-6 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 357425-87-7 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 357425-88-8 CAPLUS

CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 357425-89-9 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)

09/402,010




● HCl

RN 357425-90-2 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 357425-91-3 CAPLUS  
CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-5-fluoro-7,8,9,10-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357425-92-4 CAPLUS  
CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 357426-16-5

RL: RCT (Reactant)

(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)

RN 357426-16-5 CAPLUS

CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



IT 230615-62-0P 230615-63-1P 230615-64-2P

230615-67-5P 230615-68-6P 230615-70-0P

230615-73-3P 230615-74-4P 230615-86-8P

357425-95-7P 357425-98-0P 357425-99-1P

357426-00-7P 357426-01-8P 357426-02-9P

357426-05-2P 357426-06-3P 357426-07-4P


357426-08-5P 357426-09-6P 357426-10-9P

357426-17-6P 357426-18-7P 357426-19-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of aryl-fused azapolycyclic compds. as nicotine binding inhibitors)

RN 230615-62-0 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 230615-63-1 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid, 5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/402,010




RN 230615-64-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
NAME)



RN 230615-68-6 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)



RN 230615-70-0 CAPLUS


09/402,010

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-73-3 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-74-4 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-86-8 CAPLUS


CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357425-95-7 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-chloro-6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

09/402,010




RN 357425-98-0 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357425-99-1 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-00-7 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-3-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-01-8 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 3-ethyl-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)

09/402,010




RN 357426-02-9 CAPLUS

CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-4-methyl-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-05-2 CAPLUS

CN 6,10-Methano-2H-pyrido[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-06-3 CAPLUS


CN 6,10-Methano-6H-pyrido[2,3-h][3]benzazepine, 2-chloro-7,8,9,10-tetrahydro-8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 357426-07-4 CAPLUS

CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid, 2-chloro-6,7,9,10-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)







RN 357426-08-5 CAPLUS  
 CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,  
 6,7,9,10-tetrahydro-2-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)



RN 357426-09-6 CAPLUS  
 CN 6,10-Methano-8H-pyrido[2,3-h][3]benzazepine-8-carboxylic acid,  
 2-chloro-5-fluoro-6,7,9,10-tetrahydro-, methyl ester (9CI) (CA INDEX  
 NAME)




RN 357426-10-9 CAPLUS  
 CN 6,10-Methano-2H-pyrazino[2,3-h][3]benzazepin-2-one, 1,6,7,8,9,10-hexahydro-  
 8-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 357426-17-6 CAPLUS  
 CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
 1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester,  
 monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 357426-18-7 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
1-(2,2-dimethylpropyl)-5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl  
ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 357426-19-8 CAPLUS

CN 6,10-Methano-8H-pyrazino[2,3-h][3]benzazepine-8-carboxylic acid,  
6,7,9,10-tetrahydro-2,3-dimethyl-, 1,1-dimethylethyl ester,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/402,010

~~EP 3~~ ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS

AN 2001:152263 CAPLUS

DN 134:198095

TI Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug

IN Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 18 pp.


CODEN: EPXXDW

DT **Patent**

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1078637	A2	20010228	EP 2000-307254	20000823
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001072604	A2	20010321	JP 2000-254041	20000824
PRAI	US 1999-151089	P	19990827		
AB	Pharmaceutical compns. are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, redn. of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.				
IT	230615-75-5 249296-44-4 328055-77-2 328055-78-3 328055-79-4 328055-83-0 328055-87-4 328055-88-5 328055-89-6 328055-90-9 328055-92-1 328055-93-2 328055-98-7				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nicotine and other drug addiction treatment with compns. contg. nicotine receptor agonists and antidepressants or anxiolytic agents)				
RN	230615-75-5 CAPLUS				
CN	5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)				



RN 249296-44-4 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- (9CI)  
(CA INDEX NAME)

09/402,010




RN 328055-77-2 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 328055-78-3 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepin-1(2H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 328055-79-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)



RN 328055-83-0 CAPLUS


CN 5,9-Methano-2H-isothiazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



09/402,010


RN 328055-87-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-  
(9CI) (CA INDEX NAME)




RN 328055-88-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-  
(9CI) (CA INDEX NAME)




RN 328055-89-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-  
dimethyl- (9CI) (CA INDEX NAME)



RN 328055-90-9 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-  
phenyl- (9CI) (CA INDEX NAME)



RN 328055-92-1 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-  
methyl- (9CI) (CA INDEX NAME)

09/402,010




RN 328055-93-2 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepine, 3,5,6,7,8,9-hexahydro- (9CI)  
(CA INDEX NAME)



RN 328055-98-7 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-  
(9CI) (CA INDEX NAME)



09/402,010

L23 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS

AL 2000:553442 CAPLUS

DN 133:168383

TI Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms

IN Caille, Dominique; George, Pascal; Jegham, Samir; Robineau, Pascale; Scatton, Bernard; Zivkovic, Branimir

PA Sanofi-Synthelabo, Fr.

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT **Patent**

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000045846	A1	20000810	WO 2000-FR193	20000128
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	FR 2788982	A1	20000804	FR 1999-1144	19990202
	EP 1150715	A1	20011107	EP 2000-901660	20000128
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	FR 1999-1144	A	19990202		
	WO 2000-FR193	W	20000128		

OS MARPAT 133:168383

AB The invention concerns novel pharmaceutical compns. contg. nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for treating tobacco withdrawal symptoms. A bilayer tablet contained befloxtone 5, lactose 66, microcryst. cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine polacrylix 5, microcryst. cellulose 20 povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and lactose q.s. 100% in the second layer.

IT **287973-24-4 287973-25-5 287973-32-4**

RL: BAC (Biological activity or effector, except adverse); THU


(Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. nicotine or ligand of nicotine receptors and monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms)

RN 287973-24-4 CAPLUS


CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

09/402,010




RN 287973-25-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 287973-32-4 CAPLUS

CN 5,9-Methanopyrrolo[3,4-h][3]benzazepine-1,3(2H,5H)-dione, 5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




09/402,010

applicants

L23 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS  
 AN 1999:451282 CAPLUS  
 DN 131:102204  
 TI Preparation of 1,5-methano-3-benzazepines and analogs as nicotinic  
 receptor ligands  
 IN Coe, Jotham Wadsworth; Brooks, Paige Roanne Palmer  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935131	A1	19990715	WO 1998-IB1813	19981113
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9896416	A1	19990726	AU 1998-96416	19981113
	BR 9814592	A	20001017	BR 1998-14592	19981113
	EP 1044189	A1	20001018	EP 1998-950274	19981113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2002500218	T2	20020108	JP 2000-527532	19981113
	NO 2000003422	A	20000829	NO 2000-3422	20000630
PRAI	US 1997-70245	P	19971231		
	WO 1998-IB1813	W	19981113		
OS	MARPAT 131:102204				
GI					



AB Title compds. [I; R1 = H, alk(en)yl, alkoxyethyl, oxoalkyl, etc.; R2,R3 = H, halo, (di)(alkyl)amino, alkyl, etc.; R2R3 = atoms to complete a ring] were prepd. Thus, 2-FC6H4Br was cyclocondensed with cyclopentadiene and the product osmylated to give 1,2,3,4-tetrahydro-1,4-methanonaphthalene-2,3-diol which was treated with NaIO4 and the product cyclocondensed with PhCH2NH2 to give, after deprotection, I (R1-R3 = H). Data for biol. activity of I were given.

IT 230615-07-3P 230615-09-5P 230615-10-8P  
 230615-11-9P 230615-12-0P 230615-13-1P  
 230615-14-2P 230615-15-3P 230615-16-4P  
 230615-17-5P 230615-18-6P 230615-19-7P  
 230615-20-0P 230615-21-1P 230615-22-2P  
 230615-23-3P 230615-24-4P 230615-25-5P

09/402,010

230615-26-6P 230615-33-5P 230615-39-1P

230615-40-4P 230615-44-8P 230615-45-9P


230615-46-0P 230615-75-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1,5-methano-3-benzazepines and analogs as nicotinic receptor ligands)

RN 230615-07-3 CAPLUS


CN 5,9-Methano-5H-thiazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-09-5 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-10-8 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

09/402,010

RN 230615-11-9 CAPLUS


5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-12-0 CAPLUS


5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-13-1 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1,2-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-14-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-propyl-,  
monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-15-3 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-butyl-1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-16-4 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-17-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-18-6 CAPLUS


CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-19-7 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1,5,6,7,8,9-hexahydro-2-methyl-1-(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-20-0 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-1,5,6,7,8,9-hexahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-21-1 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-2,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-22-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine, 1-(2,2-dimethylpropyl)-, 1,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-23-3 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-24-4 CAPLUS


CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-25-5 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-26-6 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/402,010



● HCl

RN 230615-33-5 CAPLUS


CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-39-1 CAPLUS

CN 5,9-Methanopyrrolo[2,3-h][3]benzazepin-2(1H)-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-40-4 CAPLUS

CN 5,9-Methano-2H-oxazolo[4,5-h][3]benzazepin-2-one, 3,5,6,7,8,9-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




09/402,010



● HCl

RN 230615-44-8 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 230615-45-9 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 230615-46-0 CAPLUS


CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

09/402,010




● HCl

RN 230615-75-5 CAPLUS  
CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-  
(9CI) (CA INDEX NAME)




IT 230615-62-0P 230615-63-1P 230615-64-2P  
230615-67-5P 230615-68-6P 230615-70-0P  
230615-73-3P 230615-74-4P 230615-86-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) ..  
(prepn. of 1,5-methano-3-benzazepines and analogs as nicotinic receptor  
ligands)  
RN 230615-62-0 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
NAME)




RN 230615-63-1 CAPLUS  
CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-2-methyl-1-propyl-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)

09/402,010




RN 230615-64-2 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 230615-67-5 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
1-butyl-5,6,8,9-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
NAME)



RN 230615-68-6 CAPLUS

CN 5,9-Methanoimidazo[4,5-h][3]benzazepine-7(1H)-carboxylic acid,  
5,6,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-, 1,1-dimethylethyl ester  
(9CI) (CA INDEX NAME)




RN 230615-70-0 CAPLUS

CN 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro-8-


09/402,010

(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-73-3 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 230615-74-4 CAPLUS

CN 5,9-Methano-5H-oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 230615-86-8 CAPLUS

CN 5,9-Methano-5H-isoxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-3-methyl-7-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT